NEW YORK (GenomeWeb) – Clinical proteomics firm SISCAPA Assay Technologies is developing a 12-protein panel for longitudinal tracking of cardiovascular disease, kidney disease, and diabetes.

The panel will use mass spec-based analysis of dried blood spot samples, which should improve patient convenience and lower costs, SAT CEO Leigh Anderson told GenomeWeb. He added that the company is currently in discussions with several large clinical reference labs about possibly implementing the panel as a CLIA test.